Abstract
Rapid emergence of drug resistant Human Immunodeficiency virus (HIV) variants and severe side effects of anti-HIV drugs limit the efficacy of existing anti-HIV therapies. Efforts are being made to develop newer anti-HIV agents. Few newer anti-HIV agents reached the different clinical phases of development and appear promising for future therapy. The present article highlights the current status of available anti-HIV drugs, emerging anti-HIV drug agents and recent anti-HIV drugs patents information.
Keywords: AIDS, antiretroviral drugs, clinical studies, emerging drugs, HIV, patents, NRTIs, zidovudine, Rilpivirine, Apricitabine
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Current Drug Discovery Technologies
Anti-Infective Agents
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Drug Design and Discovery
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
An Epidemiological Update on COVID -19
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
99